Results 21 to 30 of about 390,233 (255)

Pancreatic cancer [PDF]

BMJ, 2014
In recent years, it has become clear that the current standard therapeutic options for pancreatic cancer are not adequate and still do not meet the criteria to cure patients suffering from this lethal disease. Although research over the past decade has shown very interesting and promising new therapeutic options for these patients, only minor clinical ...
Ajith K, Siriwardena, Alison M, Siriwardena   +1 more
openaire   +4 more sources

Combined resection of the transpancreatic common hepatic artery preserving the gastric arterial arcade without arterial reconstruction in hepatopancreatoduodenectomy: a case report

Surgical Case Reports, 2018
Background Surgeons sometimes must plan pancreatoduodenectomy (PD) for patients with a variant common hepatic artery (CHA) branching from the superior mesenteric artery (SMA) penetrating the pancreatic parenchyma, known as a transpancreatic CHA (tp-CHA).
Takashi Miyata, Yusuke Yamamoto, Teiichi Sugiura, Yukiyasu Okamura, Takaaki Ito, Ryo Ashida, Sunao Uemura, Yoshiyasu Kato, Katsuhisa Ohgi, Atsushi Kohga, Tsuneyuki Uchida, Shusei Sano, Katsuhiko Uesaka   +12 more
doaj   +1 more source

Pancreatic Cancer [PDF]

Annual Review of Pathology: Mechanisms of Disease, 2007
The past two decades have witnessed an explosion in our understanding of pancreatic cancer, and it is now clear that pancreatic cancer is a disease of inherited (germ-line) and somatic gene mutations. The genes mutated in pancreatic cancer include KRAS2, p16/CDKN2A, TP53, and SMAD4/DPC4, and these are accompanied by a substantial compendium of genomic ...
Anirban, Maitra, Ralph H, Hruban
openaire   +2 more sources

Role of tumor mutation burden-related signatures in the prognosis and immune microenvironment of pancreatic ductal adenocarcinoma

Cancer Cell International, 2021
Background High tumor mutation burden (TMB) has gradually become a sensitive biomarker for predicting the response to immunotherapy in many cancers, including lung, bladder and head and neck cancers.
Rong Tang, Xiaomeng Liu, Wei Wang, Jie Hua, Jin Xu, Chen Liang, Qingcai Meng, Jiang Liu, Bo Zhang, Xianjun Yu, Si Shi   +10 more
doaj   +1 more source

From the Immune Profile to the Immunoscore: Signatures for Improving Postsurgical Prognostic Prediction of Pancreatic Neuroendocrine Tumors

Frontiers in Immunology, 2021
ObjectiveImmune infiltration plays an important role in tumor development and progression and shows promising prognostic value in numerous tumors. In this study, we aimed to identify the role of immune infiltration in pancreatic neuroendocrine tumors ...
Miaoyan Wei, Miaoyan Wei, Miaoyan Wei, Miaoyan Wei, Miaoyan Wei, Jin Xu, Jin Xu, Jin Xu, Jin Xu, Jin Xu, Jie Hua, Jie Hua, Jie Hua, Jie Hua, Jie Hua, Qingcai Meng, Qingcai Meng, Qingcai Meng, Qingcai Meng, Qingcai Meng, Chen Liang, Chen Liang, Chen Liang, Chen Liang, Chen Liang, Jiang Liu, Jiang Liu, Jiang Liu, Jiang Liu, Jiang Liu, Bo Zhang, Bo Zhang, Bo Zhang, Bo Zhang, Bo Zhang, Wei Wang, Wei Wang, Wei Wang, Wei Wang, Wei Wang, Xianjun Yu, Xianjun Yu, Xianjun Yu, Xianjun Yu, Xianjun Yu, Si Shi, Si Shi, Si Shi, Si Shi, Si Shi   +49 more
doaj   +1 more source

Novel agents for pancreatic ductal adenocarcinoma: emerging therapeutics and future directions

Journal of Hematology & Oncology, 2018
A poor prognosis of pancreatic ductal adenocarcinoma (PDAC) associated with chemoresistance has not changed for the past three decades. A multidisciplinary diagnosis followed by surgery and chemo(radiation)therapy is the main treatment approach. However,
Yiyin Zhang, Chao Yang, He Cheng, Zhiyao Fan, Qiuyi Huang, Yu Lu, Kun Fan, Guopei Luo, Kaizhou Jin, Zhengshi Wang, Chen Liu, Xianjun Yu   +11 more
doaj   +1 more source

PARP inhibitors in pancreatic cancer: molecular mechanisms and clinical applications

Molecular Cancer, 2020
Pancreatic cancer is a highly lethal disease with a poor prognosis, and existing therapies offer only limited effectiveness. Mutation gene sequencing has shown several gene associations that may account for its carcinogenesis, revealing a promising ...
Heng Zhu, Miaoyan Wei, Jin Xu, Jie Hua, Chen Liang, Qingcai Meng, Yiyin Zhang, Jiang Liu, Bo Zhang, Xianjun Yu, Si Shi   +10 more
doaj   +1 more source

Crosstalk between cancer-associated fibroblasts and immune cells in the tumor microenvironment: new findings and future perspectives

Molecular Cancer, 2021
Cancer-associated fibroblasts (CAFs), a stromal cell population with cell-of-origin, phenotypic and functional heterogeneity, are the most essential components of the tumor microenvironment (TME).
Xiaoqi Mao, Jin Xu, Wei Wang, Chen Liang, Jie Hua, Jiang Liu, Bo Zhang, Qingcai Meng, Xianjun Yu, Si Shi   +9 more
doaj   +1 more source

PRMT5 enhances tumorigenicity and glycolysis in pancreatic cancer via the FBW7/cMyc axis

Cell Communication and Signaling, 2019
Background The epigenetic factor protein arginine methyltransferase 5 (PRMT5) has been reported to play vital roles in a wide range of cellular processes, such as gene transcription, genomic organization, differentiation and cell cycle control.
Yi Qin, Qiangsheng Hu, Jin Xu, Shunrong Ji, Weixing Dai, Wensheng Liu, Wenyan Xu, Qiqing Sun, Zheng Zhang, Quanxing Ni, Bo Zhang, Xianjun Yu, Xiaowu Xu   +12 more
doaj   +1 more source

A novel immune checkpoint score system for prognostic evaluation in pancreatic adenocarcinoma

BMC Gastroenterology, 2023
Background Pancreatic adenocarcinoma (PAAD) remains a lethal malignancy making the detection of novel prognostic biomarkers urgent. Limited studies have investigated the predictive capability of immune checkpoints in PAAD. Method Gene expression data and
Yusheng Chen, Xuan Lin, Xuan Zou, Yunzhen Qian, Yu Liu, Ruijie Wang, Xu Wang, Xianjun Yu, Chen Liu, He Cheng   +9 more
doaj   +1 more source